Clinical trials of antiangiogenic therapy for hepatocellular carcinoma
- 22 February 2016
- journal article
- review article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 21 (2) , 213-218
Abstract
Angiogenesis is a promising therapeutic target to inhibit tumor growth. This review summarizes data from clinical trials of antiangiogenic agents in hepatocellular carcinoma. A systematic search of PubMed was performed to identify clinical trials of specific antiangiogenic agents in hepatocellular carcinoma treatment, particularly phase III trials involving treatment guidelines for advanced hepatocellular carcinoma. Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma. Two large-scale, randomized phase III trials using sorafenib involving patients with unresectable HCC showed a significant survival benefit compared with placebo control groups. However, subsequent phase III trials of antiangiogenic agents in hepatocellular carcinoma have failed to improve survival compared with standard treatment protocols using sorafenib. The efficacy of antiangiogenic agents in combination with other drugs, transarterial chemoembolization, and surgical resection is currently being investigated. Future research is expected to optimize antiangiogenic therapies in combination with standard treatment with sorafenib.Keywords
This publication has 43 references indexed in Scilit:
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular CarcinomaGastroenterology, 2016
- Immunological landscape and immunotherapy of hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2015
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Hepatocellular carcinomaThe Lancet, 2012
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Predictors of Extrahepatic Recurrence After Curative Hepatectomy for Hepatocellular CarcinomaAnnals of Surgical Oncology, 2010
- Improved Results of a Surgical Resection for the Recurrence of Hepatocellular Carcinoma After Living Donor Liver TransplantationAnnals of Surgical Oncology, 2010
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008